BMRN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BioMarin Pharmaceutical Inc (BMRN) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has some positive developments, such as new data on VOXZOGO and potential future catalysts, the technical indicators, mixed analyst ratings, and lack of strong trading signals suggest a cautious approach. The stock's near-term performance appears uncertain, and there are no immediate signs of significant upside potential.
The MACD is negatively expanding and below 0, indicating bearish momentum. RSI is neutral at 40.49, and moving averages are converging, suggesting indecision. The stock is trading near its pivot level of 56.152, with resistance at 57.68 and support at 54.624. Overall, the technical indicators do not provide a clear bullish signal.
VOXZOGO demonstrated significant growth velocity improvements in children with hypochondroplasia and a favorable safety profile.
Phase 1 results for BMN 333 show potential as a new standard of care for achondroplasia.
BioMarin plans to submit a supplemental New Drug Application for VOXZOGO in Q3 2026, which could drive future growth.
Mixed Phase 3 results for BMN401 in ENPP1 deficiency, with lack of clinical improvement despite biomarker benefits, raising questions about its regulatory path.
Analysts have lowered price targets and reduced probabilities of success for BMN
The stock shows a 70% chance of declining in the short term based on candlestick pattern analysis.
No financial data is available for the latest quarter, making it difficult to assess recent growth trends. However, past updates indicate revenue growth driven by enzyme therapies and Voxzogo, with guidance reflecting contributions from the Amicus acquisition.
Analyst ratings are mixed, with some maintaining Buy ratings and others lowering price targets due to concerns about BMN401 and competitive risks for Voxzogo. Price targets range from $50 to $120, reflecting uncertainty about the company's near-term prospects.
